PriceTargets.com logo

Evolus - EOLS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.00
  • Forecasted Upside: 82.11%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$12.63 As of 11/20/2024 01:00 AM ET
▲ +0.24 (1.94%)

This chart shows the closing price for EOLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evolus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EOLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EOLS

Analyst Price Target is $23.00
▲ +82.11% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Evolus in the last 3 months. The average price target is $23.00, with a high forecast of $27.00 and a low forecast of $20.00. The average price target represents a 82.11% upside from the last price of $12.63.

This chart shows the closing price for EOLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Evolus. This rating has held steady since April 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
11/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
10/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight
9/13/2024BarclaysBoost TargetOverweight ➝ Overweight$16.00 ➝ $20.00
9/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
8/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight
5/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00
5/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00
5/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00
1/29/2024BarclaysUpgradeEqual Weight ➝ Overweight$10.00 ➝ $16.00
1/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00
12/20/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
8/3/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
8/3/2023HC WainwrightBoost TargetBuy ➝ Buy$16.00 ➝ $27.00
7/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$16.00
6/7/2023MizuhoBoost Target$17.00 ➝ $20.00
5/26/2023Truist FinancialBoost Target$14.00 ➝ $18.00
5/10/2023HC WainwrightBoost Target$15.00 ➝ $16.00
3/9/2023HC WainwrightReiterated RatingBuy$15.00
3/9/2023Needham & Company LLCReiterated RatingBuy$18.00
2/13/2023Needham & Company LLCReiterated RatingBuy$18.00
1/19/2023Leerink PartnersBoost TargetOutperform$18.00 ➝ $20.00
1/19/2023MizuhoBoost TargetBuy$15.00 ➝ $17.00
11/9/2022HC WainwrightReiterated RatingBuy
6/23/2022Needham & Company LLCInitiated CoverageBuy$18.00
5/12/2022BarclaysUpgradeUnderweight ➝ Equal Weight$8.00 ➝ $10.00
4/28/2022BarclaysBoost Target$7.00 ➝ $8.00
3/4/2022Cantor FitzgeraldReiterated RatingOverweight$20.00
3/4/2022HC WainwrightReiterated RatingBuy$15.00
1/20/2022Truist FinancialUpgradeHold ➝ Buy$11.00
11/12/2021Leerink PartnersReiterated RatingBuy$18.00
11/3/2021HC WainwrightLower TargetBuy$22.00 ➝ $15.00
10/18/2021Leerink PartnersReiterated RatingOutperform
8/8/2021Leerink PartnersReiterated RatingBuy$18.00
5/19/2021Leerink PartnersReiterated RatingBuy$18.00
5/13/2021BarclaysLower TargetUnderweight$8.00 ➝ $7.00
5/6/2021MizuhoUpgradeNeutral ➝ Buy$15.00
4/8/2021HC WainwrightReiterated RatingBuy$20.00 ➝ $22.00
3/30/2021MizuhoBoost TargetNeutral$9.00 ➝ $15.00
3/24/2021HC WainwrightBoost TargetBuy$18.00 ➝ $20.00
2/24/2021Truist FinancialDowngradeBuy ➝ Hold$12.00
2/22/2021BarclaysBoost TargetPositive ➝ Underweight$4.00 ➝ $8.00
2/22/2021Cantor FitzgeraldBoost TargetOverweight$11.00 ➝ $20.00
2/22/2021MizuhoBoost TargetNeutral$5.00 ➝ $9.00
2/22/2021HC WainwrightBoost TargetBuy$6.00 ➝ $18.00
2/19/2021Stifel NicolausBoost TargetBuy$11.00 ➝ $25.00
12/17/2020HC WainwrightLower TargetBuy$8.00 ➝ $6.00
9/22/2020MizuhoReiterated RatingHold$5.00
8/11/2020HC WainwrightBoost TargetBuy$7.00 ➝ $8.00
7/7/2020SunTrust BanksLower TargetBuy$12.00 ➝ $6.00
7/7/2020MizuhoDowngradeBuy ➝ Neutral$8.00 ➝ $3.00
7/7/2020HC WainwrightLower TargetBuy$15.00 ➝ $7.00
5/13/2020BarclaysLower TargetUnderweight$9.00 ➝ $4.00
5/12/2020HC WainwrightReiterated RatingBuy$15.00
5/12/2020SunTrust BanksLower TargetBuy$18.00 ➝ $12.00
5/12/2020MizuhoLower TargetBuy$10.00 ➝ $8.00
4/30/2020Wells Fargo & CompanyLower TargetEqual Weight$10.00 ➝ $5.00
4/20/2020HC WainwrightReiterated RatingBuy$16.00
4/17/2020MizuhoLower TargetBuy$12.00 ➝ $10.00
4/16/2020Stifel NicolausLower TargetBuy$30.00 ➝ $25.00
4/3/2020Leerink PartnersLower TargetOutperform$25.00 ➝ $15.00
3/27/2020HC WainwrightLower TargetBuy$31.00 ➝ $16.00
2/27/2020BarclaysReiterated RatingSell$9.00
2/26/2020HC WainwrightLower TargetBuy$34.00 ➝ $31.00
2/25/2020MizuhoReiterated RatingBuy$20.00
2/20/2020HC WainwrightLower TargetBuy$37.00 ➝ $34.00
2/5/2020MizuhoInitiated CoverageBuy$20.00
1/21/2020MizuhoReiterated RatingBuy$30.00
11/26/2019Leerink PartnersInitiated CoverageOutperform$25.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 12 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 6 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 8 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 10 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 8 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 8 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Evolus logo
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Read More

Today's Range

Now: $12.63
Low: $12.17
High: $12.65

50 Day Range

MA: $15.75
Low: $11.88
High: $17.49

52 Week Range

Now: $12.63
Low: $9.29
High: $17.82

Volume

429,714 shs

Average Volume

658,760 shs

Market Capitalization

$799.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Evolus?

The following Wall Street sell-side analysts have issued research reports on Evolus in the last year: Barclays PLC, Cantor Fitzgerald, HC Wainwright, and Needham & Company LLC.
View the latest analyst ratings for EOLS.

What is the current price target for Evolus?

0 Wall Street analysts have set twelve-month price targets for Evolus in the last year. Their average twelve-month price target is $23.00, suggesting a possible upside of 82.1%. HC Wainwright has the highest price target set, predicting EOLS will reach $27.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $20.00 for Evolus in the next year.
View the latest price targets for EOLS.

What is the current consensus analyst rating for Evolus?

Evolus currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EOLS will outperform the market and that investors should add to their positions of Evolus.
View the latest ratings for EOLS.

What other companies compete with Evolus?

Other companies that are similar to Evolus include Adamas Pharmaceuticals, MoonLake Immunotherapeutics, HUTCHMED, Agios Pharmaceuticals and Verona Pharma. Learn More about companies similar to Evolus.

How do I contact Evolus' investor relations team?

Evolus' physical mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company's listed phone number is (949) 284-4555 and its investor relations email address is [email protected]. The official website for Evolus is www.evolus.com. Learn More about contacing Evolus investor relations.